Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S)

Diabetes Therapy

Volumn 8, Issue 5, 2017, Pages 1123-1134

  Awata, Takuya ^a   Shimada, Akira ^b   Maruyama, Taro ^c   Oikawa, Yoichi ^b   Yasukawa, Nobuyuki ^a   Kurihara, Susumu ^b   Miyashita, Yumi ^b   Hatano, Masako ^b   Ikegami, Yuichi ^b   Matsuda, Masafumi ^d   Niwa, Masataka ^e   Kazama, Youichiro ^f   Tanaka, Shoichiro ^g   Kobayashi, Tetsuro ^h  

^a International University of Health and Welfare   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c SAITAMA SOCIAL INSURANCE HOSPITAL   (Japan)

^d SAITAMA MEDICAL UNIVERSITY   (Japan)

^e Iidabashi Eye Clinic   (Japan)

^f Kazama Medical Clinic   (Japan)

^g Ai Home Clinic   (Japan)

^h Okinaka Memorial Institute for Medical Research   (Japan)

Author keywords

Dipeptidyl peptidase 4 (DPP 4) inhibitor; Intervention; Latent autoimmune diabetes in adults (LADA); Prevention; Sitagliptin; Slowly progressive type 1 diabetes (SPIDDM); Type 1 diabetes

Indexed keywords

C PEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; METFORMIN; PIOGLITAZONE; SITAGLIPTIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HYPOGLYCEMIA; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 85030845011     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-017-0299-7     Document Type: Article

References (40)

1. Atkinson MA, von Herrath M, Powers AC, Clare-Salzler M. Current concepts on the pathogenesis of type 1 diabetes–considerations for attempts to prevent and reverse the disease. Diabetes Care. 2015;38(6):979–88.
2. Kobayashi T, Tamemoto K, Nakanishi K, et al. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care. 1993;16(5):780–8.
3. Tanaka S, Ohmori M, Awata T, et al. Diagnotic criteria for slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM) (2012): report by the comitteeon slowly progressive insulin-dependent (type 1) diabetes mellitus of the Japan Diabetes Society. Diabetol Int. 2015;6(1):1–7.
4. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes. 1993;42(2):359–62.
5. Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes Care. 2001;24(8):1460–7.
6. Stenstrom G, Gottsater A, Bakhtadze E, Berger B, Sundkvist G. Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function, and treatment. Diabetes. 2005;54(Suppl 2):S68–72.
7. Tanaka S, Awata T, Shimada A, et al. Clinical characteristics of slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM): 1st subcommittee report on SPIDDM, comittee on type 1 diabetes, Japan Diabetes Society. J Japan Diab Soc (in Japanese). 2011;54(1):65–75.
8. Tuomi T, Carlsson A, Li H, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes. 1999;48(1):150–7.
9. Zhou Z, Xiang Y, Ji L, et al. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes. 2013;62(2):543–50.
10. Maddaloni E, Lessan N, Al Tikriti A, Buzzetti R, Pozzilli P, Barakat MT. Latent autoimmune diabetes in adults in the United Arab Emirates: clinical features and factors related to insulin-requirement. PLoS ONE. 2015;10(8):e0131837.
11. Pozzilli P. Type 1 diabetes mellitus in 2011: heterogeneity of T1DM raises questions for therapy. Nat Rev Endocrinol. 2012;8(2):78–80.
12. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383(9911):69–82.
13. Kobayashi T, Nakanishi K, Murase T, Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes. 1996;45(5):622–6.
14. Pozzilli P, Maddaloni E, Buzzetti R. Combination immunotherapies for type 1 diabetes mellitus. Nat Rev Endocrinol. 2015;11(5):289–97.
15. Maruyama T, Tanaka S, Shimada A, et al. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab. 2008;93(6):2115–21.
16. Brophy S, Davies H, Mannan S, Brunt H, Williams R. Interventions for latent autoimmune diabetes (LADA) in adults. Cochrane Database Syst Rev. 2011;9:CD006165.
17. Suarez-Pinzon WL, Cembrowski GS, Rabinovitch A. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice. Diabetologia. 2009;52(8):1680–2.
18. Tian L, Gao J, Hao J, et al. Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology. 2010;151(7):3049–60.
19. Kim SJ, Nian C, McIntosh CH. Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4 + T-cell migration through incretin-dependent and -independent pathways. Diabetes. 2010;59(7):1739–50.
20. Zhao Y, Yang L, Xiang Y, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains beta-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study. J Clin Endocrinol Metab. 2014;99(5):E876–80.
21. Johansen OE, Boehm BO, Grill V, et al. C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study. Diabetes Care. 2014;37(1):e11–2.
22. Buzzetti R, Pozzilli P, Frederich R, Iqbal N, Hirshberg B. Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA). Diabetes Metab Res Rev. 2016;32(3):289–96.
23. Shimada A, Shigihara T, Okubo Y, Katsuki T, Yamada Y, Oikawa Y. Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes. Diabetes Metab Res Rev. 2011;27(8):951–3.
24. Zhou Z, Li X, Huang G, et al. Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev. 2005;21(2):203–8.
25. Kobayashi T, Tanaka S, Shimada A, Maruyama T, et al. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes: response to Buzzetti et al. Diabetes Care. 2007;30(11):e126.
26. Awata T, Kuzuya T, Matsuda A, Iwamoto Y, Kanazawa Y. Genetic analysis of HLA class II alleles and susceptibility to type 1 (insulin-dependent) diabetes mellitus in Japanese subjects. Diabetologia. 1992;35(5):419–24.
27. Alonso N, Julian MT, Carrascal J, et al. Type 1 diabetes prevention in NOD Mice by targeting DPPIV/CD26 is associated with changes in CD8(+)T effector memory subset. PLoS ONE. 2015;10(11):e0142186.
28. Kasuga A, Maruyama T, Nakamoto S, Ozawa Y, Suzuki Y, Saruta T. High-titer autoantibodies against glutamic acid decarboxylase plus autoantibodies against insulin and IA-2 predicts insulin requirement in adult diabetic patients. J Autoimmun. 1999;12(2):131–5.
29. Shimada A, Maruyama T, Suzuki R, et al. Anti-GAD65 antibody titer may be important in assessing T-cell response in anti-GAD65 + diabetes with residual beta-cell function. Diabetes Care. 1999;22(10):1759.
30. Lima-Martinez MM, Guerra-Alcala E, Contreras M, Nastasi J, Noble JA, Polychronakos C. One year remission of type 1 diabetes mellitus in a patient treated with sitagliptin. Endocrinol Diabetes Metabol Case Rep. 2014;2014:140072.
31. Kandasamy N, Lennox G, Annamalai AK, Maguire G, Adler AI. Sitagliptin in glutamic acid decarboxylase antibody-positive diabetes mellitus. Endocr Pract. 2012;18(4):e65–8.
32. Rapti E, Karras S, Grammatiki M, et al. Combined treatment with sitagliptin and vitamin D in a patient with latent autoimmune diabetes in adults. Endocrinol Diabetes Metabol Case Rep. 2016;2016:150136.
33. Pinheiro MM, Pinheiro FM, Torres MA. Four-year clinical remission of type 1 diabetes mellitus in two patients treated with sitagliptin and vitamin D3. Endocrinol Diabetes Metabol Case Rep. 2016;2016:16–0099.
34. Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med. 2011;28(10):1176–81.
35. Garg SK, Moser EG, Bode BW, et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract. 2013;19(1):19–28.
36. Griffin KJ, Thompson PA, Gottschalk M, Kyllo JH, Rabinovitch A. Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2014;2(9):710–8.
37. Hirata T, Shimada A, Morimoto J, Maruyama T. Slowly progressive type 1 diabetes treated with metformin for five years after onset. Intern Med. 2013;52(23):2635–7.
38. Bahne E, Hansen M, Bronden A, Sonne DP, Vilsboll T, Knop FK. Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin. Diabetes Obes Metab. 2016;18(10):955–61.
39. Hadjiyanni I, Siminovitch KA, Danska JS, Drucker DJ. Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells. Diabetologia. 2010;53(4):730–40.
40. Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015;528(7581):262–6.